This case focuses on the 2001 negotiations between Mytex pharmaceuticals and the U.S. Food and Drug Administration (FDA). Outcome of the negotiations will determine the new label for the blockbuster drug for arthritis Mytex, Flaxil. Negotiations rather qualitative and different from the typical price negotiations with which students are familiar. However, at stake was $ 500 million in sales Flaxil and security of millions of patients. (A) case represents the views and Mytex FDA on new evidence Flaxil can have side effects. "Hide
by Gregory Barron Source: Harvard Business School 10 pages. Publication Date: August 24, 2008. Prod. #: 909001-PDF-ENG
Related Case Solutions & Analyses:
The Kid Grows Up: Decisions at the Sundance Institute
Chairman Zhang and Broad Group: Growth Dilemmas
Food Store of the Northern Lakes Cooperative
WorldSpace: Digital Radio for the Developing World
EasyEverything: The Internet Shop (Abridged)
Praying for Prosperity
University of Wyoming
Operations Fundamentals- Final Exams
St Joseph Care Group: Internal And External Analysis
StakeHolders
